EMA committee recommends melflufen label expansion to third-line myeloma treatmentAccess, Myeloma22 September 2026
IMS President Philippe Moreau previews this months IMS Annual MeetingConferences, Myeloma2 September 2026
EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myelomaAccess, Myeloma3 July 2026